invobioscience.com (INVO): Debts to Book Capitalization

Brandmark of invobioscience.com (INVO)

The share of borrowed funds in the balance sheet capitalization of INVO Bioscience, Inc. (INVO) on the GURU.Markets chart currently stands at 3.81, which is attributed to asset integration following a major merger. Business stability relies on unique incubators for the automatic maturation of embryos. Management is focusing on developing its own clinics and implementing affordable infertility treatment methods.

INVO - INVO Bioscience Debts to Net Assets over the range 07/04/2022 - 04/28/2025
Original product of invobioscience.com

To assess the fundamental stability of INVO Bioscience, Inc. (INVO), it is essential to analyze the balance between borrowed funds and equity. This ratio measures the degree of financial autonomy, determining the company's dependence on external creditors for its development. The trend of the debt-to-capitalization ratio demonstrates the risk of default against scaling rates. For the owner of the unique INVOcell technology, low debt confirms the independence of its pricing power. An optimal metric level guarantees the expansion of this accessible IVF method without excessive financial pressure.

Competitors of INVO Bioscience, Inc.

BSX: Debts to Book Capitalization|Debts to Book Value edwards.com EW|RMD: Debts to Book Capitalization|PODD - Debt to Book Value|Zimmer Biomet - Debts to Book Capitalization|CooperSurgical (COO) - Debts to Net Assets|ALGN (Align Technology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization GMED|Debt to Book Capitalization Ratio TransMedics Organ Care System (TMDX)|Debt to Book Capitalization Ratio Alphatec Holdings (ATEC)|Debts to Book Capitalization AORT|ENOV - Debts to Net Assets|Debt to Book Value Integra LifeSciences|ESTA - Debts to Book Capitalization Ratio|Debts to Book Capitalization BBNX|IRADIMED Corp (IRMD) - Debts to Book Value|Debts to Book Capitalization Embecta Inc. (EMBC)|Debt to Book Value Ratio Tandem Corp (TNDM)|AxoGen, Inc. (AXGN) - Debt to Book Value|Debt to Net Assets Ratio SIBN (si-bone.com)|Orthofix - Debt to Book Capitalization Ratio|Debt to Book Value Bioventus Inc BVS|KIDS (OrthoPediatrics Inc.) - Debts to Book Capitalization|TMCI - Debts to Book Value|Debts to Book Capitalization Strata Critical Medical Inc|carlsmed.com (CARL) - Debt to Book Value Ratio|RXST: Debts to Book Capitalization|Debts to Net Assets ClearPoint|Debts to Book Capitalization STXS (Stereotaxis Corp)|Debt to Book Value Neuronetics, Inc (STIM)|Debts to Book Capitalization SGHT (Sight Sciences, Inc.)|Orchestra BioMed Inc. - Debts to Book Capitalization|ANIK - Debt to Book Capitalization Ratio|InspireMD Inc (NSPR) - Debt to Book Capitalization Ratio|Debt to Book Value zhjmedical.com ZJYL|Vivani Medical (VANI) - Debt to Net Assets Ratio|Debts to Book Capitalization XTNT (Xtant Medical Holdings, Inc.)|Debts to Book Value NMTC|MODD: Debt to Book Capitalization Ratio|Debt to Net Assets Myomo Inc. MYO|Debt to Book Value COCH (Envoy Medical, Inc)|Debts to Book Capitalization Vivos Therapeutics Inc VVOS|Debts to Book Capitalization NVNO (enVVeno Medical)|SINT: Debts to Net Assets|Debt to Book Capitalization Ratio Tenon Medical (TNON)|LFWD (ReWalk Robotics) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio AMIX|Debt to Book Value INVO Fertility Corp|Bone Biologics - Debts to Book Capitalization|Debts to Book Value AXNX (axonics.com)|BIOL - Debt to Book Capitalization Ratio|DYNT - Debt to Book Value Ratio|Debt to Book Value Paragon 28 Corp FNA